Open Access<p>Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents</p>
Author(s) -
Yingqi Feng,
Boan Li,
Fan Feng,
Chen Yong-Shou,
Yixin Ren,
Heng Zhang,
Shuang Cao
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s244474
Subject(s) - sorafenib , hepatocellular carcinoma , regorafenib , pi3k/akt/mtor pathway , cancer research , discovery and development of mtor inhibitors , medicine , pharmacology , targeted therapy , kinase , chemistry , cancer , apoptosis , biochemistry , colorectal cancer
Although molecular-targeted agents are still the first choice for advanced hepatocellular carcinoma (HCC) treatment, the therapeutic efficacy of these agents is not satisfactory. Recently, the mammalian target of rapamycin (mTOR) is considered to be a promising molecular target that can enhance the sensitivity of HCC cells to antitumor therapy. However, the reported mTOR inhibitors have some shortcomings, and novel mTOR inhibitors need to be developed to enhance the antitumor effect of molecularly targeted agents on advanced HCC.